Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Division of Clinical and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):770-780. doi: 10.1016/S2468-1253(22)00020-6. Epub 2022 May 5.
Patients with chronic liver disease are often diagnosed during an index presentation to hospital with decompensated cirrhosis or liver-related events, and these presentations are associated with high mortality. However, there is often a long asymptomatic phase, in which there is an opportunity for earlier diagnosis and interventions to prevent progression to advanced disease. Therefore, strategies for early diagnosis and interventions (including behavioural changes and pharmacological treatments) that prevent patients progressing to cirrhosis and its associated complications probably have substantial benefits for patients and health-care services. Many community pathways have been generated. Some pathways focus on abnormal liver function tests as a starting point to diagnose liver disease. Other pathways target groups at greater risk of chronic liver disease-particularly people with harmful alcohol consumption, type 2 diabetes, and obesity. This systematic review summarises the existing strategies available for the early detection or risk stratification of liver disease, focusing primarily on alcohol-related liver disease and non-alcoholic fatty liver disease. Conducting randomised clinical trials that compare different strategies will be essential to elucidate which pathways are acceptable to patients, feasible, provide high diagnostic accuracy for the detection of liver disease, improve liver-related outcomes, and are most cost-effective at the population level.
慢性肝病患者在因失代偿性肝硬化或与肝脏相关的事件到医院就诊时经常被诊断出,这些就诊与高死亡率相关。然而,患者通常有一个无症状的长阶段,在此期间有机会进行早期诊断和干预,以防止疾病进展为晚期。因此,预防患者进展为肝硬化及其相关并发症的早期诊断和干预策略(包括行为改变和药物治疗)可能对患者和医疗保健服务有很大的益处。已经制定了许多社区途径。一些途径侧重于肝功能检查异常作为诊断肝脏疾病的起点。其他途径针对慢性肝病风险较高的人群-特别是有大量饮酒、2 型糖尿病和肥胖的人群。本系统综述总结了现有用于早期发现或疾病风险分层的策略,主要关注酒精性肝病和非酒精性脂肪性肝病。开展比较不同策略的随机临床试验对于阐明哪些途径被患者接受、可行、为肝脏疾病的检测提供高诊断准确性、改善肝脏相关结局以及在人群层面最具成本效益至关重要。